Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
MoonLake Immunotherapeutics a un objectif de cours consensus de $69.57, basé sur les évaluations des 15 analystes. Le plus élevé est de $104 attribué par Oppenheimer le juin 25, 2024, et le plus bas est de $16 attribué par Jefferies le novembre 11, 2022. Les 3 dernières évaluations d'analystes ont été publiées par Goldman Sachs, RBC Capital et Wolfe Research le août 6, 2025, juin 3, 2025 et mai 19, 2025. Avec un objectif de cours moyen de $70 entre Goldman Sachs, RBC Capital et Wolfe Research, il y a une variation implicite de 18.12% upside pour MoonLake Immunotherapeutics à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
Goldman Sachs
RBC Capital
Wolfe Research
Needham
HC Wainwright & Co.
1calculé à partir des notes des analystes
Notes d'analystes pour MoonLake
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/06/2025 | 38.37% | Goldman Sachs | $74 → $82 | Maintains | Buy | |||
06/03/2025 | 13.06% | RBC Capital | $67 → $67 | Reiterates | Outperform → Outperform | |||
05/19/2025 | 2.94% | Wolfe Research | → $61 | Upgrade | Peer Perform → Outperform | |||
05/13/2025 | 11.37% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
04/30/2025 | 11.37% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
03/18/2025 | 13.06% | RBC Capital | → $67 | Initiates | → Outperform | |||
02/27/2025 | 23.19% | Goldman Sachs | $82 → $73 | Maintains | Buy | |||
02/27/2025 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
02/27/2025 | 11.37% | Needham | $62 → $66 | Maintains | Buy | |||
01/17/2025 | 38.37% | Goldman Sachs | $62 → $82 | Upgrade | Neutral → Buy | |||
01/10/2025 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
11/14/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
11/08/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
11/05/2024 | 23.19% | Wedbush | $92 → $73 | Assumes | Outperform → Outperform | |||
10/15/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
09/23/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
09/12/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
09/12/2024 | 4.62% | Needham | $62 → $62 | Reiterates | Buy → Buy | |||
09/09/2024 | — | Cantor Fitzgerald | — | Reiterates | → Overweight | |||
08/26/2024 | — | Wolfe Research | — | Downgrade | Outperform → Peer Perform | |||
08/08/2024 | 4.62% | Needham | $66 → $62 | Maintains | Buy | |||
07/01/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
06/25/2024 | 75.5% | Oppenheimer | → $104 | Initiates | → Outperform | |||
06/11/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
06/10/2024 | 11.37% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
05/17/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
05/08/2024 | 11.37% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
05/08/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
04/23/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
04/11/2024 | 68.75% | HC Wainwright & Co. | $100 → $100 | Reiterates | Buy → Buy | |||
04/09/2024 | 11.37% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
04/02/2024 | 4.62% | Goldman Sachs | → $62 | Initiates | → Neutral | |||
03/13/2024 | 55.25% | Wedbush | $92 → $92 | Reiterates | Outperform → Outperform | |||
03/11/2024 | 55.25% | Wedbush | $92 → $92 | Reiterates | Outperform → Outperform | |||
03/11/2024 | 11.37% | Needham | $66 → $66 | Reiterates | Buy → Buy | |||
03/11/2024 | 68.75% | HC Wainwright & Co. | $75 → $100 | Maintains | Buy | |||
03/04/2024 | 26.56% | HC Wainwright & Co. | $75 → $75 | Reiterates | Buy → Buy | |||
03/01/2024 | 55.25% | Wedbush | $92 → $92 | Reiterates | Outperform → Outperform | |||
03/01/2024 | 11.37% | Needham | → $66 | Reiterates | Buy → Buy | |||
02/15/2024 | — | Wolfe Research | — | Initiates | → Outperform | |||
12/18/2023 | 16.44% | Stifel | $66 → $69 | Maintains | Buy | |||
12/08/2023 | 21.5% | Citigroup | → $72 | Initiates | → Buy | |||
12/01/2023 | 55.25% | Wedbush | → $92 | Reiterates | Outperform → Outperform | |||
11/27/2023 | 26.56% | HC Wainwright & Co. | → $75 | Reiterates | Buy → Buy | |||
11/16/2023 | 55.25% | Wedbush | $86 → $92 | Maintains | Outperform | |||
11/15/2023 | 29.94% | Guggenheim | $70 → $77 | Maintains | Buy | |||
11/08/2023 | 31.62% | Cantor Fitzgerald | → $78 | Reiterates | Overweight → Overweight | |||
11/07/2023 | 45.12% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
11/06/2023 | 45.12% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
11/02/2023 | 24.87% | Stifel | → $74 | Initiates | → Buy | |||
10/16/2023 | 45.12% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
10/16/2023 | 28.25% | Needham | → $76 | Reiterates | Buy → Buy | |||
10/03/2023 | 45.12% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
09/18/2023 | 9.69% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
09/18/2023 | 45.12% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
09/14/2023 | 9.69% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
09/12/2023 | -0.44% | Barclays | $41 → $59 | Maintains | Equal-Weight | |||
09/12/2023 | 9.69% | Cantor Fitzgerald | → $65 | Reiterates | Overweight → Overweight | |||
09/12/2023 | 26.56% | HC Wainwright & Co. | → $75 | Reiterates | Buy → Buy | |||
09/12/2023 | 28.25% | Needham | → $76 | Reiterates | Buy → Buy | |||
08/31/2023 | 28.25% | Needham | → $76 | Initiates | → Buy | |||
08/14/2023 | 45.12% | Wedbush | → $86 | Reiterates | Outperform → Outperform | |||
08/14/2023 | 26.56% | HC Wainwright & Co. | → $75 | Reiterates | Buy → Buy | |||
07/31/2023 | 45.12% | Wedbush | $61 → $86 | Maintains | Outperform | |||
07/26/2023 | 26.56% | HC Wainwright & Co. | → $75 | Reiterates | Buy → Buy | |||
07/17/2023 | 26.56% | HC Wainwright & Co. | $37 → $75 | Maintains | Buy | |||
07/03/2023 | 9.69% | Cantor Fitzgerald | $29 → $65 | Maintains | Overweight | |||
06/27/2023 | -30.81% | Barclays | $28 → $41 | Maintains | Equal-Weight | |||
06/26/2023 | 9.69% | Guggenheim | $51 → $65 | Maintains | Buy | |||
06/21/2023 | -37.56% | HC Wainwright & Co. | → $37 | Reiterates | Buy → Buy | |||
06/15/2023 | -52.75% | Barclays | → $28 | Initiates | → Equal-Weight | |||
05/15/2023 | -37.56% | HC Wainwright & Co. | → $37 | Reiterates | Buy → Buy | |||
05/10/2023 | -37.56% | HC Wainwright & Co. | $30 → $37 | Reiterates | → Buy | |||
05/04/2023 | -49.38% | HC Wainwright & Co. | → $30 | Reiterates | → Buy | |||
05/01/2023 | -13.94% | Guggenheim | → $51 | Initiates | → Buy | |||
04/20/2023 | -49.38% | HC Wainwright & Co. | $28 → $30 | Maintains | Buy | |||
03/22/2023 | -44.31% | Wedbush | → $33 | Initiates | → Outperform | |||
03/21/2023 | -52.75% | HC Wainwright & Co. | → $28 | Reiterates | → Buy | |||
03/20/2023 | -51.06% | Cantor Fitzgerald | $23 → $29 | Maintains | Overweight | |||
03/09/2023 | -39.25% | BTIG | → $36 | Initiates | → Buy | |||
03/06/2023 | -61.19% | Cantor Fitzgerald | → $23 | Reiterates | → Overweight | |||
02/14/2023 | -61.19% | Cantor Fitzgerald | → $23 | Initiates | → Overweight | |||
02/13/2023 | -52.75% | HC Wainwright & Co. | → $28 | Reiterates | → Buy | |||
02/03/2023 | -52.75% | HC Wainwright & Co. | → $28 | Reiterates | → Buy | |||
11/11/2022 | -73% | Jefferies | → $16 | Initiates | → Buy |
FAQ
Quel est le cours indicatif de l'action MoonLake (MLTX) ?
Le dernier objectif de prix pour MoonLake (NASDAQ:MLTX) a été rapporté par Goldman Sachs le août 6, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $82.00 s'attendant à ce que MLTX se rise dans les 12 prochains mois (un possible changement de 38.37% upside). 19 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour MoonLake (MLTX) ?
La dernière note d'analyste pour MoonLake (NASDAQ:MLTX) a été fournie par Goldman Sachs, et MoonLake maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour MoonLake (MLTX) ?
La dernière amélioration pour MoonLake Immunotherapeutics a eu lieu le mai 19, 2025 lorsque Wolfe Research a augmenté leur objectif de prix à $61. Wolfe Research avait précédemment a peer perform pour MoonLake Immunotherapeutics.
Quand a eu lieu la dernière dégradation pour MoonLake (MLTX) ?
La dernière réduction pour MoonLake Immunotherapeutics a eu lieu le août 26, 2024 lorsque Wolfe Research a changé leur objectif de prix de N/A à N/A pour MoonLake Immunotherapeutics.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour MoonLake (MLTX) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de MoonLake, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour MoonLake a été déposée le août 6, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers août 6, 2026.
La note d'analyste pour MoonLake (MLTX) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de MoonLake (MLTX) était un maintenu avec un objectif de prix de $74.00 à $82.00. Le prix actuel de MoonLake (MLTX) est de $59.26, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.